Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Gilead Sciences (NASDAQ ... and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead’s trial is assessing the combo’s safety and efficacy in 443 subjects. Credit: JHVEPhoto/Shutterstock. Gilead Sciences has reported positive topline data from the randomised Phase III ...

Gilead Sciences recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women in the U.K.—a group that, according to the partners, has long been ...